Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 2017-2026

  Delaney IV, William E ^a   Miller, Thomas G ^a   Isom, Harriet C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; LAMIVUDINE; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; BACULOVIRUS; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS REPLICATION;

EID: 0032838507     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.2017     Document Type: Article

References (39)

1. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22. (Comment, 349:3-4.)
2. Beasley, R. P., L. Y. Hwang, C. C. Lin, and C. S. Chien. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet ii:1129-1133.
3. Ben-Ari, Z., D. Shmueli, E. Mor, E. Shaharabani, N. Bar-Nathan, Z. Shapira, and R. Tur-Kaspa. 1997. Beneficial effect of lamivudine pre-and post-liver transplantation for hepatitis B infection. Transplant. Proc. 29:2687-2688.
4. Cammack, N., P. Rouse, C. L. Marr, P. J. Reid, R. E. Boehme, J. A. Coates, C. R. Penn, and J. M. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
5. Chang, C. M., K. S. Jeng, C. P. Hu, S. J. Lo, T. S. Su, L. P. Ting, C. K. Chou, S. H. Han, E. Pfaff, J. Salfeld, et al. 1987. Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line. EMBO J. 6:675-680.
6. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
7. Civitico, G. M., and S. A. Locarnini. 1994. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 203:81-89.
8. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
9. Davis, L. G., M. D. Dibner, and J. F. Battey. 1986. Preparation and analysis of RNA from eukaryotic cells, p. 129-156. In Basic methods in molecular biology. Elsevier Science Publishing, Co., Inc., New York, N.Y.
10. Delaney, W. E., IV, and H. C. Isom. 1998. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28:1134-1145.
11. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661. (Comment, 333:1704-1705.)
12. Doong, S. L., C. H. Tsai, R. F. Schinazi, D. C. Liotta, and Y. C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
13. Evans, A. A., M. Fine, and W. T. London. 1997. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for Interferon therapy. J. Infect. Dis. 176:845-850.
14. Grellier, L., D. Mutimer, M. Ahmed, D. Brown, A. K. Burroughs, K. Rolles, P. McMaster, P. Beranek, F. Kennedy, H. Kibbler, P. McPhillips, E. Elias, and G. Dusheiko. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215. (Erratum, 349:364, 1997.)
15. Hirsch, R., R. Colgrove, and D. Ganem. 1988. Replication of duck hepatitis B virus in two differentiated human hepatoma cell lines after transfection with cloned viral DNA. Virology 167:136-142.
16. Honkoop, P., R. A. de Man, and H. G. Niesters. 1998. Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy. Ann. Intern. Med. 128:697. (Letter.)
17. Katkov, W. N. 1996. Hepatitis vaccines. Med. Clin. North Am. 80:1189-1200. (Review.)
18. Knowles, B. B., C. C. Howe, and D. P. Aden. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499.
19. Kock, J., and H. J. Schlicht. 1993. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. 67:4867-4874.
20. Korba, B. E. 1996. In vitro evaluation of combination therapies against hepatitis B virus replication. Antivir. Res. 29:49-51.
21. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
22. Kruining, J., R. A. Heijtink, and S. W. Schalm. 1995. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J. Hepatol. 22:263-267.
23. Lai, C. L., C. K. Ching, A. K. Tung, E. Li, J. Young, A. Hill, B. C. Wong, J. Dent, and F. C. Wu. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
24. Moraleda, G., J. Sapulelli, C. E. Aldrich, D. Averett, L. Condreay, and W. S. Mason. 1997. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:9392-9399.
25. Nevens, F., J. Main, P. Honkoop, D. L. Tyrrell, J. Barber, M. T. Sullivan, J. Fevery, R. A. de Man, and H. C. Thomas. 1997. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
26. Niederau, C., T. Heintges, S. Lange, G. Goldmann, C. M. Niederau, L. Mohr, and D. Haussinger. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334: 1422-1427. (Comment, 334:1470-1471.)
27. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Analysis and cloning of eukaryotic genomic DNA, p. 9.1-9.62. In N. Ford, C. Nolan, and M. Ferguson (ed.), Molecular cloning. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
28. Sells, M. A., M. L. Chen, and G. Acs. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84:1005-1009.
29. Sells, M. A., A. Z. Zelent, M. Shvartsman, and G. Acs. 1988. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62:2836-2844.
30. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
31. Tsurimoto, T., A. Fujiyama, and K. Matsubara. 1987. Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA. Proc. Natl. Acad. Sci. USA 84:444-448.
32. Tuttleman, J. S., C. Pourcel, and J. Summers. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47:451-460.
33. Tyrrell, D. L. J., K. Fischer, K. Savani, W. Tan, and L. Jewell. 1993. Treatment of chimpanzees and ducks with lamivudine, 2′-3′-dideoxy-3′thiacytidine, results in a rapid suppression of hepadnaviral DNA in sera. Clin. Investig. Med. 16:B77. (Abstract.)
34. Ueda, K., T. Tsurimoto, T. Nagahata, O. Chisaka, and K. Matsubara. 1989. An in vitro system for screening anti-hepatitis B virus drugs. Virology 169: 213-216.
35. Wei Y., J. E. Tavis, and D. Ganem. 1996. Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses. J. Virol. 70:6455-6458.
36. Wong, D. K., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:312-323. (Comment, 120(Suppl. 1):12, 1994.)
37. Wong, D. K., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:312-323. (Comment, 120(Suppl. 1):12, 1994.)
38. World Health Organization. 1996. Fighting disease, fostering development. World health report. (Executive summary.) World Health Organization, Geneva, Switzerland.
39. Yaginuma, K., Y. Shirakata, M. Kobayashi, and K. Koike. 1987. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc. Natl. Acad. Sci. USA 84:2678-2682.